REFERENCES

1. Aronson DC, Meyers RL. Malignant tumors of the liver. Sem Ped Surg 2016;25:265-75.

2. Tanaka Y, Inoue T, Horie H. International pediatric liver cancer pathological classification: current trend. Int J Clin Oncol 2013;18:946-54.

3. Prokurat A, Kluge P, Kosciesza A, Perek D, Kappeler A, Zimmermann A. Transitional liver cell tumors (TLCT) in older children and adolescents: A novel group of aggressive hepatic tumors expressing beta-catenin. Med Pediatr Oncol 2002;39:510-8.

4. Torbenson M. Review of the clinicopathological features of fibrolamellar carcinoma. Adv Anat Pathol 2007;14:217-23.

5. Eggert T, McGlynn KA, Duffy A, Manns MP, Greten TF, Altekruse SF. Fibrolamellar hepatocellular carcinoma in the USA: 2000-2010: a detailed report on frequency, treatment and outcome based on the Surveillance, Epidemiology, and End Results database. Unit Europ Gastroenterol J 2013;1:351-7.

6. Katzenstein HM, Krailo MD, Malogolowkin MH, et al. Fibrolamellar hepatocellular carcinoma in children and adolescents. Cancer 2003;97:2006-12.

7. Weeda VB, Murawski M, McCabe AJ, et al. Fibrolamellar variant of hepatocellular carcinoma does not have a better survival than conventional hepatocellular carcinoma in children: results and treatment recommendations for the Childhood Liver Tumour Strategy Group (SIOPEL) experience. Eur J Cancer 2013;49:2698-704.

8. Chang M, You S, Chen C, et al. Taiwan Hepatoma Study Group. Long-term effects of hepatitis B immunization of infants in preventing liver cancer. Gastroenterol 2016;151:472-80.

9. Meyers RL. Tumors of the liver in children. Surg Oncol 2007;16:195-203.

10. Eichenmüller M, Trippel F, Kreuder M, Beck A, Schwarzmayr T, Haberle B, et al. The genomic landscape of hepatoblastoma and and their progenies with HCC-like features. J Hepato ;61:1312-20.

11. Jain S, Singhal S, Lee P, Xu R. Molecular genetics of hepatocellular neoplasia. Am J Transl Res 2010;2:105-18.

12. Weeda VB, Aronson DC, Verheij J, Lamers WH. Is hepatocellular carcinoma the same disease in children and adults Comparison of histology, molecular background and treatment in pediatric and adult patients. Pediatr Blood Cancer 2019;66:e27475.

13. Bruix J, Qin S, Merle P, et al. RESORCE Investigators. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomized, double-blind, placebo/controlled, phase 3 trial. Lancet 2017;389:56-66.

14. Schmid I, Haberle B, Albert MH, et al. Sorafenib and cisplatin-doxorubicin (PLADO) in pediatric hepatocellular carcinoma. Pediatr Blood Cancer 2012;58:539-44.

15. Aronson DC, Weeda VB, Maibach R, et al. Childhood Liver Tumour Strategy Group (SIOPEL). Microscopically positive resection margin after hepatoblastoma resection: what is the impact on prognosis? Eur J Cancer 2019;106:126-32.

16. Ziogas IA. . Benedetti DJ, Matsuoka LK, et al. Surgical management of pediatric hepatocellular carcinoma: An analysis of the National Cancer Database. J Pediatr Surg 2020;S0022-3468(20)30433-4.

17. Czauderna P, Mackinlay G, Perilongo G, et al. Liver Tumors Study Group of the International Society of Pediatric Oncology. Hepatocellular carcinoma in children: Results of the first prospective study of the International Society of Pediatric Oncology group. J Clin Oncol 2002;20:2798-804.

18. Murawski M, Weeda VB, Maibach RM, Morland B, Roebuck D, Zimmerman A, et al. Hepatocellular Carcinoma in Children: Does modified platinum- and doxorubicin-based chemotherapy increase tumor resectability and change outcome? J Clin Oncol 2016;34:1050-6.

19. Schmid I, von Schweinitz D. Pediatric hepatocellular carcinoma: challenges and solutions. J Hepatocell Carcinoma 2017;4:15-21.

20. Katzenstein HM, Krailo MD, Malogolowkin MH, et al. Hepatocellular Carcinoma in Children and Adolescents: Results from the Pediatric Oncology Group and the Children’s Cancer Group Intergroup Study. J Clin Oncol 2002;20:2789-97.

21. Richly H, Schultheis B, Adamietz IA, et al. Combination of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma: Results from a phase I extension trial. Eur J Cancer 2009;45:579-87.

22. Liu Y, Yue H, Xu S, et al. First-line gemcitabine and oxaliplatin (GEMOX) plus sorafenib, followed by sorafenib as maintenance therapy, for patients with advanced hepatocellular carcinoma: a preliminary study. Int J Clin Oncol 2015;20:952-9.

23. Assenat E, Pageaux GP, Thézenas S, et al. Sorafenib alone vs. sorafenib plus GEMOX as 1^st-line treatment for advanced HCC: the phase II randomized PRODIGE 10 trial. Br J Cancer 2019;120:896-902.

24. Gras P, Truant S, Boige V, et al. Prolonged complete response after GEMOX chemotherapy in a patient with advanced fibrolamellar hepatocellular carcinoma. Case Rep Oncol 2012;5:69-72.

25. Haines K, Sarabia SF, Alvarez KR, et al. Characterization of pediatric hepatocellular carcinoma reveals genomic heterogeneity and diverse signaling pathway activation. Pediatr Blood Cancer 2019;66:e27745.

26. Cho SJ. Pediatric liver tumors: Updates in classification. Surg Pathol Clin 2020;13:601-23.

27. Ranganathan S, Lopez-Terrada D, Alaggio R. Hepatoblastoma and pediatric hepatocellular carcinoma: An update. Pediatr Dev Pathol 2020;23:79-95.

28. Aguado A, Ristagno R, Towbin AJ, et al. Transarterial radioembolization with yttrium-90 of unresectable primary hepatic malignancy in children. Pediatr Blood Cancer 2019;66:e27510.

29. Kallini JR, Gabr A, Salem R, Lewandowski RJ. Transarterial radioembolization with yttrium-90 for the treatment of hepatocellular carcinoma. Adv Ther 2016;33:699-714.

30. Weiss KE, Sze DY, Rangaswami AA, et al. Transarterial chemoembolization in children to treat unresectable hepatocellular carcinoma. Pediatr Transplant 2018;22:e13187.

31. Pompili M, Saviano A, de Matthaeis N, et al. Long-term effectiveness of resection and radiofrequency ablation for single hepatocellular carcinoma </=3 cm. Results of a multicenter Italian survey. J Hepatol 2013;59:89-97.

32. Hetzer B, Vogel GF, Entenmann A, et al. Stereotactic radiofrequency ablation of a variety of liver masses in children. Int J Hypertherm 2020;37:1074-81.

33. Diana M, Schiraldi L, Liu Y-Y, et al. High intensity focused ultrasound (HIFU) applied to hepato-biliopancreatic and the digestive system-current state of the art and future perspectives. HepatoBiliary Surg Nutr 2016;5:329-44.

34. Wang S, Yang C, Zhang J, et al. First experience of high-intensity focused ultrasound combined with transcatheter arterial embolization as local control for hepatoblastoma. Hepatology 2014;59:170-7.

35. Napoli A, Mastantuono M, Cavallo Marincola B, et al. Osteoid osteoma: MRguided focused ultrasound for entirely noninvasive treatment. Radiology 2013;267:514-21.

36. Sharma KV, Yarmolenko PS, Eranki A, Partanen A, Celik H, Kim A. Magnetic Resonance Imaging-guided High-intensity Focused Ultrasound Applications in Pediatrics: Early Experience at Children's National Medical Center. Top Magn Reson Imaging 2018;27:45-51.